Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG and GCSF in New Onset Type 1 Diabetes
NCT02215200Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Dec 2014
- Primary completion
- Aug 2017
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of antithymocyte globulin rabbit, pegfilgrastim in type 1 diabetes mellitus (T1D), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Started Dec 2014; status: completed.
02
Drugs
antithymocyte globulin rabbitpegfilgrastim
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02215200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02215200.